Pharmaceutical

Bayer looks to expand Kerendia label to include heart failure

Bayer adds three new Phase III heart failure studies to the Kidney and type 2 diabetes drug, Kerendia, clinical development programme.

Sep 1, 2023 - 20:00
Bayer looks to expand Kerendia label to include heart failure
Bayer adds three new Phase III heart failure studies to the Kidney and type 2 diabetes drug, Kerendia, clinical development programme.
Read the original article

Tags:

Previous Article

NexImmune to lay off over half of its employees

Next Article

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

To build trust among LA’s unhoused, a street medicine team turns to technology

To build trust among LA’s unhoused, a street medicine t...

Apr 5, 2023

Gilead and Cognizant expand deal to expedite digital transformation

Gilead and Cognizant expand deal to expedite digital tr...

Jul 25, 2023

STAT+: Colombia proceeds with plans to issue a compulsory license for an HIV medicine sold by GSK’s ViiV

STAT+: Colombia proceeds with plans to issue a compulso...

Feb 7, 2024